CoChat

Neuroprotective effect of SGLT2 inhibitors.

Open access
Pawlos, Agnieszka, Broncel, Marlena, Woźniak, Ewelina, Gorzelak-Pabiś, Paulina · 2021 · Molecules

The DOI matches its Crossref record; 122 of the 124 references it cites were found in a registry or an index; 21 of the 97 sources its claims cite were checked for support.

Abstract

Patients with diabetes are at higher risk of cardiovascular diseases and cognitive impairment. SGLT2 inhibitors (Empagliflozin, Canagliflozin, Dapagliflozin, Ertugliflozin, Sotagliflozin) are newer hypoglycemic agents with many pleiotropic effects. In this review, we discuss their neuroprotective potential. SGLT2 inhibitors (SGLT2i) are lipid-soluble and reach the brain/serum ratio from 0.3 to 0.5. SGLT receptors are present in the central nervous system (CNS). Flozins are not fully SGLT2-selective and have an affinity for the SGLT1 receptor, which is associated with protection against ischemia/reperfusion brain damage. SGLT2i show an anti-inflammatory and anti-atherosclerotic effect, including reduction of proinflammatory cytokines, M2 macrophage polarization, JAK2/STAT1 and NLRP3 inflammasome inhibition, as well as cIMT regression. They also mitigate oxidative stress. SGLT2i improve endothelial function, prevent remodeling and exert a protective effect on the neurovascular unit, blood-brain barrier, pericytes, astrocytes, microglia, and oligodendrocytes. Flozins are also able to inhibit AChE, which contributes to cognitive improvement. Empagliflozin significantly increases the level of cerebral BDNF, which modulates neurotransmission and ensures growth, survival, and plasticity of neurons. Moreover, they may be able to restore the circadian rhythm of mTOR activation, which is quite a novel finding in the field of research on metabolic diseases and cognitive impairment. SGLT2i have a great potential to protect against atherosclerosis and cognitive impairment in patients with type 2 diabetes mellitus.

Overview

CoChat Summary

TL;DR

This narrative review summarizes proposed neuroprotective mechanisms of SGLT2 inhibitors in type 2 diabetes, atherosclerosis, and cognitive impairment, including anti-inflammatory, antioxidant, anti-atherosclerotic, AChE-inhibiting, BDNF-increasing, and mTOR-rhythm-restoring effects. It concludes that flozins have potential but that long-term clinical trials are needed to establish clinical relevance.

Key findings

  • SGLT2 inhibitors are lipid-soluble and cross the blood-brain barrier, with brain/serum AUC ratios of 0.3 for canagliflozin and dapagliflozin and 0.5 for empagliflozin; SGLT1/SGLT2 are expressed in the CNS, and SGLT1 inhibition is linked to protection against ischemia/reperfusion brain damage.
  • Anti-inflammatory and anti-atherosclerotic effects include reduced proinflammatory cytokines, M2 macrophage polarization, JAK2/STAT1 and NLRP3 inflammasome inhibition, and cIMT regression; empagliflozin reduced cIMT by 7.9% (p < 0.0001) after 3 months, and canagliflozin lowered IL-6 by 26.6% (p = 0.010) after 2 years.
  • AChE inhibition may contribute to cognitive improvement: canagliflozin Ki = 0.12859 µM with estimated brain concentration ~3 µM, enough to inhibit AChE; empagliflozin Ki = 0.177 µM with brain concentration 0.5 µM, also enough; dapagliflozin Ki = 25.02 µM with brain concentration 0.3 µM, not enough.
  • Empagliflozin significantly increased cerebral BDNF in db/db mice and improved cognition; in rat cerebral ischemia/reperfusion, empagliflozin dose-dependently reduced neuronal death, infarct size, and cognitive impairment via HIF-1α/VEGF signaling; SGLT2i may restore circadian mTOR activation and mimic fasting.

Methods

  • Narrative review; no primary data collection or systematic search strategy is described.
  • Evidence synthesized includes preclinical studies (murine/rat models, ex vivo, in silico) and selected clinical studies on SGLT2 inhibitors, atherosclerosis, inflammation, oxidative stress, mTOR signaling, cerebrovascular dysfunction, and Alzheimer’s disease pathology.
  • Main analysis is a qualitative synthesis of mechanisms and reported outcomes, with one ongoing clinical trial noted: dapagliflozin in Alzheimer’s disease (NCT03801642).

Limitations

  • The paper states that long-term clinical trials are necessary to establish whether the discussed mechanisms are clinically relevant, since atheroprotective and neuroprotective effects will not be immediate and require long-term SGLT2i intake.
  • The paper notes that there is no available data on adverse CNS effects of flozins and that the exact mechanism of cardiovascular benefit has not been fully established.
  • Evident from the text: this is a narrative review without systematic methods, and many key findings come from animal, ex vivo, or in silico studies, with limited human cognitive-outcome data.

Model-written summary. Check it against the paper before relying on it.

Integrity signals

Registry

Crossref · 10.3390/molecules26237213

Cites

122 of 122 references verified0 citation errors · 0 not checkable

Statistics

Nothing to recompute.

Figures

Figure 1 Distribution of SGLT1 and SGLT2 receptors in the Central Nervous System: 1. Pyramidal cells of brain cortex; 2. Purkinje cerebellum cells; 3. Hippocampus pyramidal and granular cells; 4. Hypothalamus; 5. Microvessels; 6. Amygdala; 7. Periaqueductal grey; 8. Dorsomedial medulla—nucleus of the solitary tract (NTS).
Figure 1 Distribution of SGLT1 and SGLT2 receptors in the Central Nervous System: 1. Pyramidal cells of brain cortex; 2. Purkinje cerebellum cells; 3. Hippocampus pyramidal and granular cells; 4. Hypothalamus; 5. Microvessels; 6. Amygdala; 7. Periaqueductal grey; 8. Dorsomedial medulla—nucleus of the solitary tract (NTS).CC BY · PubMed Central
Figure 2 Influence of SGLT2 inhibitors on inflammation, atherosclerosis, and neuroinflammation. IL-1RA—Interleukin 1 Receptor Agonist, cIMT—carotid intima-media thickness, STAT1—Signal transducer and activator of transcription 1, VCAM—Vascular Cell Adhesion Molecule; ICAM-Intracellular Adhesion Molecule.
Figure 2 Influence of SGLT2 inhibitors on inflammation, atherosclerosis, and neuroinflammation. IL-1RA—Interleukin 1 Receptor Agonist, cIMT—carotid intima-media thickness, STAT1—Signal transducer and activator of transcription 1, VCAM—Vascular Cell Adhesion Molecule; ICAM-Intracellular Adhesion Molecule.CC BY · PubMed Central
Figure 3 Influence of SGLT2 inhibitors on unrestrained activation of mTOR (mechanistic/mammalian target of rapamycin). AMPK-AMP-activated protein kinase, SIRT-Sirtuin.
Figure 3 Influence of SGLT2 inhibitors on unrestrained activation of mTOR (mechanistic/mammalian target of rapamycin). AMPK-AMP-activated protein kinase, SIRT-Sirtuin.CC BY · PubMed Central
Figure 4 SGLT1 inhibition and ischemic brain damage. 1. Brain damage; 2. In the area of brain damage, there is an increase in the expression of SGLT1; 3. Sodium influx through SGLT1 receptors is associated with increased ischemia/reperfusion damage, lesion size, edema, inflammation, neuronal cell death, and decline in cognitive functions; 4. SGLT receptor blockage/knockdown was associated with improvement in damages caused by ischemia and ischemia/reperfusion damage.
Figure 4 SGLT1 inhibition and ischemic brain damage. 1. Brain damage; 2. In the area of brain damage, there is an increase in the expression of SGLT1; 3. Sodium influx through SGLT1 receptors is associated with increased ischemia/reperfusion damage, lesion size, edema, inflammation, neuronal cell death, and decline in cognitive functions; 4. SGLT receptor blockage/knockdown was associated with improvement in damages caused by ischemia and ischemia/reperfusion damage.CC BY · PubMed Central

Verification

Claims the paper makes

14 Valid · 1 Not valid · 67 Not checked · 11 Own results and interpretations

42 more claims · 2 with their cited sources checked

Create a free account to see all 93 claims and to verify the 76 references still open.

See all claims — free account
  • It may state two separate claims as one. 41
  • Probably not a substantial claim. 6
  • The quote only partly states this claim. 1

Create a free account to see these claims.

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Citations

Cites

1 retracted

Show all 122 references

Research works printed but not linked: 1

  1. Esterline, R., Oscarsson, J., and Burns, J. (2020). International Review of Neurobiology, Elsevier Inc.. [1st ed.].

Cited by

See all 326

Metadata

Authors
Pawlos, A., Broncel, M., Woźniak, E., & Gorzelak-Pabiś, P.
Affiliations
  • Medical University of Lodz (PL)
  • Laboratory of Tissue Immunopharmacology, Department of Internal Diseases and Clinical Pharmacology, Medical University of Lodz, Kniaziewicza 1/5, 91-347 Lodz, Poland
Corresponding author
Broncel, Marlena
Venue
Molecules
Publisher
MDPI AG
Published
2021-11-28
Volume
26
Issue
23
Pages
7213
ISSN
1420-3049 (ISSN-L)
OpenAlex
W3214770882
Cited by
304
References
124
Citations by year
2026: 66 · 2025: 92 · 2024: 71 · 2023: 50 · 2022: 25
FWCI
4.26
Type
journal article
Language
en
Open access
Locations
  • Molecules (publishedVersion, cc-by)
  • PubMed Central (publishedVersion, cc-by)
  • PubMed (publishedVersion)
  • DOAJ (DOAJ: Directory of Open Access Journals) (submittedVersion, cc-by-sa)
Topics
  • Life Sciences › Neuroscience › Neurology › Neuroprotection in Cerebral Ischemia
  • Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes Treatment and Management
  • Life Sciences › Neuroscience › Neurology › Neurological Disease Mechanisms and Treatments
Keywords
SGLT2 inhibitors, neuroprotection, type 2 diabetes, cognitive impairment, cardiovascular disease, anti-inflammatory activity, NLRP3 inflammasome, cerebral blood flow, neurovascular unit, blood-brain barrier, acetylcholinesterase inhibition, brain-derived neurotrophic factor, atherosclerosis
MeSH terms
Sodium-Glucose Transporter 2 Inhibitors, Animals, Brain, Diabetes Mellitus, Type 2, Humans, Hypoglycemic Agents, Neuroprotective Agents, Atherosclerosis, Sodium-Glucose Transporter 2, Cognitive Dysfunction

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

The claim verdicts this report counts are experimental: their accuracy is not yet measured.

A language model drew the claims from the paper on 2026-10-04, under version 3 of the claim definition (model deepseek-v4.1-flash, prompt extract-v3).

A second model labelled each claim on 2026-10-04 (model jev-1.13-20260917, definition revision gold-guideline-v0.2).

Cited sources are checked with a language model’s help (gpt-6-sol and qwen3.8-omni-flash).

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Neuroprotective effect of SGLT2 inhibitors. https://app.cochat.ai/papers/10.3390/molecules26237213
The paper
Pawlos, A., Broncel, M., Woźniak, E., & Gorzelak-Pabiś, P. (2021). Neuroprotective effect of SGLT2 inhibitors. Molecules. https://doi.org/10.3390/molecules26237213

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.